Four intertypic recombinants of herpes simplex virus have been shown to possess genetic information for functions characteristic of each of the two parental types. The functions were identified by (a) polyacrylamide gel electrophoresis of purified virus particles and of polypeptides synthesized in cells infected with the recombinants and (b) analysis of antigenic sites interactingwith type specific neutralizing antibody. The analysis shows that each recombinant possesses a different combination of these type specific markers. Finally we have been unable to detect recombination between herpes simplex type I and pseudorabies viruses.
INTRODUCTION
Isolates of herpes simplex virus (HSV) were first classified into two types (HSV-I and HSV-2) on the basis of antigenic differences as demonstrated by neutralization tests (Nahmias & Dowdle, I968) . They have since been shown to differ in a number of biological and biochemical properties (Figueroa & Rawls, 1969; Halliburton, 1972; Roizman, Spear & Kieff, 1972) but to have approx. 5o % of the nucleotide sequences of their DNA in common (Kieff et al. 1972; Ludwig, Biswal & Benyesh-Melnick, 1972) . That this homology is sufficient to allow gene interchange is confirmed by the demonstration of intertypic complementation and recombination by and by Esparza, Benyesh-Melnick & Schaffer (1976) .
Electrophoretic comparisons of structural polypeptides of HSV-I and HSV-2 have shown that although certain polypeptides differ in mobility within each type, others have mobilities invariant within the type; some of these have mobilities characteristic of the type while the remainder have mobilities not differing between types (Cassai, Sarmiento & Spear, I975) .
In an analogous way it has been shown that structural antigens whose interaction with corresponding antibody leads to virus neutralization may be classified as type specific or type common, that is cross-reacting (Sim & Watson, 1973) . Previous work has suggested that there are at least two type I specific determinants. One of these may correspond to the major glycoprotein region of the virus particle since an antiserum prepared by inoculation of rabbits with polyacrylamide slices containing this polypeptide region neutralized type I but not type 2 viruses (Powell et al. 1974) . The other determinant may correspond to the residual type specific activity of antiserum to Band II antigen (Watson & Wildy, I969) revealed by absorption of this antiserum with excess type 2 antigen to remove its predominant type common neutralizing activity (Sim & Watson, 1973) . It is not yet clear that these sites are different. I.w. HALLIBURTON AND OTHERS
In the present study, we report intertypic recombination between ts mutants of HSV-I and a wild-type strain of HSV-2. We shall show that recombinants isolated from such mixed infections specify polypeptides clearly characteristic of each parental type. We shall report that the recombinant viruses possess both type I and type 2 specific sites and will show how we have been able to use them to extend our knowledge of the number and nature of type specific components involved in the neutralization of virus infectivity.
METHODS

Cells and media.
BHKzI and RKI3 cells were grown as previously described (Watson et al. 1966 ) in the Glasgow modification of Eagle's medium containing Io ~o (v/v) tryptose phosphate broth and either 5 ~o (v/v) calf serum (ETC) or 5 ~o (v/v) rabbit serum respectively.
Viruses and virus assays. Two type I strains, HFEM (Watson et al. I966) and NIP I7 (Brown, I973) and two type 2 strains 3345 (Sire & Watson, I973) and HG 52 (Timbury, I97i ) were used. Intertypic recombinant viruses 34sd and zsa were kindly provided by Dr M. C. Timbury and Professor J. H. Subak-Sharpe of the Institute of Virology, University of Glasgow; they resulted from a cross between ts D (of MP 17) and ts I (of HG 52) I973) . Virus stocks were prepared in BIqK21 cells and RKI 3 cells as previously described (Watson et aL I966) and were assayed in BHK21 cells by the method described by Russell (I962) .
Mutagenesis and isolation of ts mutants. Mutagenized stocks were obtained from monolayers of BFIKzI cells incubated for 24 h at 33 °C following infection with HSV-I (strain HFEM) at an input multiplicity of Io p.f.u./cell in the presence of 5/zg/ml 5-bromodeoxyuridine (BrdUrd). The virus yields from such infections were 2"5 % of those in control cultures infected in the absence of BrdUrd. Individual plaques derived from mutagenized stocks were picked from Petri dishes containing less than 5 plaques. Plaques which contained virus with a titre at 38"5 °C/titre at 33 °C of io-3or lesswere taken asts mutants.The isolation rate of ts mutants was z-7% (7 mutants from 26I plaques) from mutagenized stock. Spontaneous mutants were isolated from 1.2 % (2 mutants from I67 plaques) of the plaques picked from control unmutagenized stock.
Complementation between pairs of mutants was measured in an infective centre assay (Timbury, I97I ) . The ability of mutants to synthesize virus DNA at the non-permissive temperature was examined as described by Halliburton & Timbury (1973) . lntertypic recombination tests. Confluent monolayers of BHK2 t cells containing approx. 4 × Io6 cells were doubly infected with a ts mutant of HSV-I and the wild-type HSV-2, 3345 at an input multiplicity of 5 p.f.u./cell (z'5 p.f.u./cell of each virus in a mixed infection and 5 p.f.u./cell of the virus in single infections). Plates were incubated at 33 °C for I8 h. Virus yields were titrated at 33 and 38.5 °C. The ts mutants derived from HFEM form large syncytial (syn) plaques on BHK21 cells whereas 3345 forms non-syncytial (syn +) plaques on BHK21 cells. Both syn and syn + plaques were counted. Recombination was assessed by comparing the ratio of syn plaques at 38"5 and 33 °C in a mixed infection with the corresponding ratio from a single infection with the mutant virus alone.
Isolation of intertypic recombinants. The yield from a mixed infection was plated out at 38"5 °C in serial Io-fold dilutions. Monolayers selected for plaque picking were carefully washed with phosphate buffered saline and syn plaques scraped and sucked into a Pasteur pipette. The contents of each plaque were suspended in ETC and treated briefly in an ultrasonic bath.
Because the syn plaques from such mixed infections were picked from dishes containing Polyaerylamide gel eleetrophoresis. Proteins were separated by electrophoresis on SDSpolyacrylamide slab gels which were fixed, stained and processed for autoradiography as described by Heine et al. (1974) . Antisera. General antisera to RKI3 cells infected with type I (HFEM) or type 2 (3345) virus were prepared as described previously (Watson et al. I966 ) by repeated immunization of rabbits with extracts of infected RK~3 cells. 'Monoprecipitin antisera' to the structural antigen Band II of herpes simplex virus type 1 were prepared in a similar manner to that described previously (Watson & Wildy, I969) by inoculation of rabbit foot pads with the corresponding precipitin line from agar-gel immunodiffusion plates.
Antiserum to the VP 7/8 region (using the nomenclature of Spear & Roizman, I972. This region corresponds to that termed VP 2/3 by Powell et al. I974) of purified type I virus (HFEM) was prepared by foot pad immunization of rabbits with polyacrylamide gel slices containing the appropriate polypeptide region as described by Powell et aL (1974) .
We are indebted to Mrs E. J. Ouldridge for preparation of antisera to Band II and to VP 7/8.
Absorption of antisera. Type I and type 2 specific (absorbed) sera were prepared as described by Sim & Watson (I973) . Briefly, I ml of general antiserum was incubated with extract of io 9 cells infected with the heterologous virus, centrifuged at 4oo00 rev/min and the supernatant fluid concentrated to its original volume by vacuum dialysis. Antiserum to the type I specific component of Band II was prepared by similar absorption of antiserum to Band II. General antisera were absorbed with recombinant antigens in a similar manner; for double absorptions with 2 recombinants, extracts of Io 9 cells infected with each virus individually were added to I ml antiserum.
Neutralization tests. Virus (4 × IO p.f.u./ml) was incubated at 25 °C for an appropriate time (usually 3 h) with an equal volume of antiserum, diluted where necessary. Surviving virus was assayed by the suspension plaque method of Russell (1962) . Antisera were Table I .
Properties of viruses used in recombination analysis
Titre of stock (p.f.u./ml) at DNA ~ phenotype 33 °C 38"5 °C at 38"5 °C Polypeptide phenotype at 38'5 °C I '6 x io 9 7"7 x Io 5 + wild-type 3'4 × Io 9 1"o × IO 4 + wild-type 5"5 )< 109 T'8 × lO 5 +_ overproduces c~-polypeptides 5"4 × IO 9 5"o x io 5 + wild-type 2'6 x io 9 5"o x io 4 + wild-type 2"I × IO 9 3"2 X IO s + wild-type 8"7 x lO 9 I.o x l& + wild-type 4"4 x lo 9 3"5 x IO 9 + wild-type 3"8 × lO 9 1-5 x Io 9 + wild-type inactivated for 30 min at 56 °C before use. In experiments where concentrated absorbed sera were used, the control pre-immune rabbit sera were absorbed with mock infected BHKzI cells and concentrated to original volume. Agar gel immunodiffusion tests were done by the method of Honess et al. (I974) in which dilutions of antiserum were tested against dilutions of antigen in a pattern arranged to allow antigen/antiserum ratios from 27/1 to I [27 to be tested on the same plate.
RESULTS
Isolation of intertypic recombinants
Two spontaneous mutants (ts LSI and 2) and five isolated in the presence of BrdUrd (ts LB z, 3, 4, 5 and 7) were used in recombination analyses. The properties of these mutants are summarized in Table I . The ratio of titres at 38"5 and 33 °C of mutant stocks ranged from 1.5 x 1o -~ (ts LB5) to I.O x to -~ (ts LB7). All mutants except ts LBz synthesized comparable amounts of virus DNA at the non-permissive temperature to wild-type virus. Polyacrylamide gel electrophoresis of extracts of cells infected at 38'5 °C showed that these mutants gave profiles indistinguishable from the wild-type virus. Under these conditions, ts LB2, which synthesized only 16 to 19 % of wild-type DNA at the restrictive temperature, overproduced the a-polypeptides (Honess & Roizman, I974) Comparisons of the ratios of syn plaques at 38"5 and 33 °C in mixed infections with each of the ts mutants and wild-type HSV-2, with the corresponding ratios for single infections with mutant virus only, indicated apparent recombination in each case (Table 2 ). By contrast, there was no evidence for recombination betwen HSV-I and pseudorabies virus.
Since ts LB2 and LB5 were representative of the two DNA/polypeptide phenotypes shown in Table I we have selected for further study one intertypic recombinant from each of the crosses ts LB2 x 3345 and ts LB 5 × 3345-These recombinants have been termed RB2 and RB5 respectively. Each grew as well as wild-type virus to give stocks with no temperature sensitivity and which gave only plaques with syncytial morphology. It is apparent that some of the polypeptides found in HSV-I (HFEM) virions were not present in identical form in HSV-z (3345) virions and vice versa. Thus, VPI-2, VP22 and VP23 of HFEM migrated slightly more slowly than their probable counterparts in 3345 whereas VP5, ¥PI2 and VPI3-I 4 of HFEM migrated slightly faster than their probable counterparts in 3345-In addition, the two areas of the gel around VP-8-8-5 and VPI7-I8 differed between the two virus types; these two areas encompassed the two major glycoprotein regions and so mobility and molarity differences are difficult to interpret since they could relate to different glycoproteins or to the same glycoproteins at different stages of processing.
Characterization of recombinants Structural polypeptides
Of the polypeptides that can be differentiated between HFEM and 3345, RB2 has VPI-z, VP5, VPI2, VPI4 and VP22 of 3345 whereas RB5 has VPI-2, VPI2, VPI4 and VP22 of 3345 but VP5 of HFEM. In addition, RB2 appears identical to the type 2 strain in the VP8-8. 5 and VPI7-I8 regions of the gel whereas RB5 is different from both HSV-I and HSV-2 in both regions. There is also a minor component in HFEM migrating slightly slower than VPt5 which is not present in 3345 or RB2 but is present in RB5. In terms of structural polypeptides therefore, RBz appears to be identical to HSV-2 whereas RB5 is more similar to HSV-2 than to HSV-I but contains two HSV-I polypeptides and differs from both HSV-I and HSV-2 in the two major glycoprotein regions of the gel. The number of ICPs is appreciably greater than the number of VPs (compare Fig. I and 2 ) and the number of type I ICPs with no exact counterpart in electrophoretic mobility or in molar concentration in HSV-2 infected cells is also greater than for VPs. A number of mobility differences can be detected between the ICPs of HFEM and 3345 plus one marked, reproducible molarity difference in ICP8 -that of 3345 being appreciably greater than that of HFEM. Many of the polypeptides specified by the recombinants can therefore be tentatively identified as characteristic of type I or of type 2. In Fig. 2 F r o m a study of a number of autoradiograms of gels of different strengths the numbers of polypeptides with electrophoretic mobilities characteristic of type I and type 2 have been determined for RB2 and RB5 (Table 3) . F r o m the results for total polypeptides it will be 
Polypeptides synthesized in infected cells
Glycosylated polypeptides in infected cells
In an analysis of glycosylated polypeptides synthesized in infected cells (Fig. 3) it can be seen that RB2 is indistinguishable from the HSV-2 parent while RB5 differs from both parents in the incorporation pattern of glucosamine. Table 3 shows the results of a number of analyses of this kind.
Antigenic sites on recombinant virus particles
All four recombinants behaved differently to their wild-type parents in that they were significantly neutralized by both type ~ and type 2 specific (absorbed) antisera (Table 4) . Type 2 specific antisera consistently neutralized RB2 and RB5 better than 34sd and 2sa. The differences with type I specific antisera were less marked but if anything neutralized 34sd and 2sa better than RB2 and RB5. All four recombinants thus possess type specific components derived from each parent; furthermore the quantitative differences suggest qualitative differences "in the particular determinants present in each recombinant.
We have confirmed these differences by neutralization experiments with general antisera absorbed with recombinants (Table 5 ). In these experiments significant neutralization has only been recorded where the following conditions were met: (i) the survival of virus incubated with an absorbed antiserum was significantly less than the Ioo% value set by the survival of the same virus incubated with pre-immune serum. (ii) The absorbed antiserum did not significantly reduce the infectivity of virus of the same strain as that used in the absorptions. (iii) The survival of a particular virus incubated with an absorbed antiserum was significantly less than the survival, after incubation with the same absorbed antiserum, of virus of the same strain as that used in the absorption. All results recorded in Table 5 are derived from at least three experiments involving at least two batches of each absorbed antiserum.
It is clear that many of the absorbed sera have retained residual neutralizing activity against both wild-type parent viruses and. other recombinants. Thus, general antiserum to 8-I (IO4-2) (95"6) 1"4 4'0 (lO6-9) (t 11.2) 2sa I-5 (IOI-2) 32"7 (IO4-6) 1.5 4'2 (lO8"4) (967 General type 2 antiserum absorbed with 34sd (lO9"3) 9"o 1.6 2-4 (IO3"8) (125"8) 5'6 8-8 2sa 7"3 (lO9.6) 3-o 2"3 (lO5-9) (9o'7) 6.o 44 RB2 (103"7) (104"5) (I01"I) (97"9) (100"8) (106'3) (86"3) (90"1)
RB5
(119"0) (102-9) (102-2) (98"2) (94"8) (87"5) (91"4) (88-3) 34sd+ 2sa
(112-o) (lO9"9) 3"8 3"2 (IO6"9) N.D. 7"7 N.D.
* Values in parentheses do not differ significantly from I00% t N.D. = not done. 
* Values in parenthesis do not differ significantly from too%. t Half dilution of antiserum.
type i virus still neutralized 2sa after absorption with 34sd and vice versa. General antiserum to type ~ absorbed with RB5 retained neutralizing activity against RB2, indicating an antigenic difference between these recombinants with respect to type I sites. Similar absorptions of general antiserum to type 2 virus revealed differences between the recombinants with respect to those type 2 specific antigenic sites capable of interaction with neutralizing antibody. Additional information on type I specific antigenic sites came from experiments with antisera of more restrictive type specificity, namely, anti VP7/8 and anti Band II type I specific antisera (Table 6 ). All recombinants and the type I parents were neutralized by antiserum to VP7/8 whereas the type 2 strains were not. However, the Band II type I specific antiserum was effective only against the type I parents and 2sa.
In analysing the results it should be noted that if a virus X is neutralized by an antiserum absorbed with virus Y then virus Y lacks antigenic site(s) present in X. Table 7 indicates a model scheme with the minimal number of sites consistent with the observations of Tables 4 to 6. The results showed that 34sd and 2sa each possess different type 2 specific sites since, when general antiserum to type 2 was absorbed with one, it still neutralized the other [lines (x) and (y)] while wild-type 2, RB2 and RB5 must all possess a third site since they were neutralized by general antiserum to type 2 absorbed with both 2sa and 34sd [line (z)].
The position with type t specific sites is more complex. Anti VP7/8 neutralized all the Watson, personal communication) , that VP7/8 does not have a single specificity and acts at more than one site. It would thus be possible that the Band II type I specific site represented one of these sites, with Band II type I specific activity being subsumed in antiserum to VP7/8. However, were this the case, since 34sd lacks Band II type I specific site [line (b)], then absorption of antiserum to VP7/8 with 34sd would be expected to neutralize zsa by residual Band II type I specific activity. In fact, absorption of antiserum to VP7/8 with 34sd removes all neutralizing activity for zsa confirming the separate identities of the VP7/8 and Band II type I specific sites. General antiserum to type I, after absorption with 2sa, neutralized 34sd and RBz but not RB5 [line (c)]. Finally, general antiserum to type I, after absorption with RB2, neutralized 34sd and zsa but not RB5 giving line (d). It will be noted that we have entered a minus sign under 2sa in this line. This is because the observed neutralization of zsa by antiserum to type I virus after absorption with RBz could be explained by line (b); RBz is negative for the Band II type r specific site represented by line (b) while 2sa is positive. Accordingly antiserum to type I absorbed with RBa would neutralize 2sa through this activity and since we are concerned to present a scheme with the minimal number of sites necessary to explain the results we have not recorded zsa as positive in line (d).
It will be seen that 34sd and zsa between them possess all the type I specific sites in L W. HALLIBURTON AND OTHERS agreement with the fact that general antiserum to type I virus has no residual neutralizing activity for any of the viruses after double absorption with 34sd and 2sa.
Agar gel immunodiffusion tests
All four recombinants gave precipitin bands in agar gel immunodiffusion tests with type ~ specific (absorbed) antiserum. Similar tests with type 2 specific (absorbed) antiserum were positive for RB2 and RB5 (which both exhibited as many precipitin bands as type 2 virus) but negative for 34sd and 2sa. The numbers of precipitin bands revealed in the various tests are shown in Table 8 . For comparative purposes Table 8 also shows the numbers of type specific sites involved in virus neutralization as determined by the analysis of Table 7 . DISCUSSION The polypeptide and glycoprotein profiles summarized in Table 3 and the antigenic results summarized in Table 8 agree in showing that the four recombinants possess characters deriving from the two parental types. Of particular significance is the fact that all the recombinants differ in the particular combination of phenotypes present. This prompts a number of suggestions for future lines of experimentation.
Firstly, analysis of a number of recombinants from a particular cross in terms of the markers we have identified and comparison with patterns of restriction enzyme cleavage of the recombinants, as compared to those of parental viruses should allow conclusions to be drawn on numbers of 'cross-overs' taking place in particular crosses.
An extension of this kind of analysis to recombinants from several crosses and comparison with physical maps derived from restriction enzyme analysis should make it possible to map the functions we have been analysing. We may allude here to the mapping of the site of the adenovirus hexon gene by relating the patterns of restriction endonuclease cleavage of recombinants of adenovirus types 2 and 5 to their classification with respect to possession of type specific hexon activity (Mautner et al. 1975) .
We may further note that from the analysis of a number of recombinants it should be possible to choose those with particular phenotype combinations for use in further genetic analysis.
All seven ts mutants of HSV-I used in this work were capable of recombination with wild-type HSV-2 although we were unable to detect any significant recombination with pseudorabies virus. This difference presumably reflects the relative ease of interchangeability of gene products between the closely related HSV-~ and HSV-2 as compared to the less closely related HSV-[ and pseudorabies viruses (Watson et al. I967; Ludwig et al. I972; Honess et al. I974) . We may note in passing that such differences may be of taxonomic significance; in the poxviridae the differing genera are defined as groups of viruses which are capable of recombining with each other and which also cross-neutralize. Viruses in the different genera do not either recombine or cross-neutralize. Pseudorabies virus does not, of course, cross-neutralize with HSV-~ (Watson et al. ~967 ) so it will be of interest to test for recombination between HSV-~ and other viruses which it does cross-neutralize.
The analysis of antigens involved in neutralization has shown all recombinants to possess both type ~ and type 2 specific sites. It will be recalled that Timbury & Subak-Sharpe 0973) noted that, in neutralization reactions with general antisera, 34sd behaved as an intermediate of the parental MPI 7 and HG5z viruses. In fact this result may be largely coincidental. That intermediate behaviour in neutralization tests does not necessarily indicate the presence of both type I and type 2 specific sites is shown by the results of Roizman et al. (I97o) on the MP strain which also exhibited neutralization kinetics with general antisera intermediate between those of HSV-I and HSV-z strains. In fact MP, unlike the recombinants, possesses only type ~ specific sites since it is neutralized by type I specific but not type 2 specific antiserum.
The antigenic analysis has proved of value in extending our knowledge of the number of target sites for neutralizing antibody. We should emphasize, however, that the model in Table 7 represents the minimal number of sites necessary to explain the experimental results. It is very possible that some of the lines in Table 7 represent multiple sites. For this reason no great significance attaches to the circumstance that RB2 apparently possesses two type specific and three type 2 specific sites, while 2sa apparently exhibits only two type I specific sites and one type 2 specific site. As we shall report in a later publication we have evidence for a higher number of type I specific sites from studies on the antigenic variability of HSV-~ strains (R. A. Killington, E. J. Ouldridge & D. H. Watson, personal communication) .
We had hoped by comparison of polypeptide and glycoprotein profiles with the results of antigenic analysis to relate antigenic sites to particular polypeptides. We have, however, been unable to relate absences of particular antigenic sites to corresponding glycoprotein absences. As we have noted, the correlation was hampered by our inability to classify some glycoproteins as characteristic of either type I or type 2, possibly because of unusual processing of glycoproteins in the recombinants.
Similar considerations arise in relation to the syn marker possessed by all the recombinants. Once again there seems to be no clear common feature in the glycoprotein patterns which could account for the property. Even accepting that we cannot assume the syn markers of HFEM and MPI7 to be necessarily the same, it is noteworthy that in 34sd and 2sa, syn is associated with predominantly type ~ antigenic and glycoprotein properties while in RB2 and RB5 it is associated with predominantly type 2 characteristics.
Nevertheless the results with a limited number of recombinants encourage the hope that a more extensive study will give us a greater insight into the molecular determinants of antigenic sites and syncytial plaque formation.
